OpsMill Transforms Infrastructure Automation with Beta Release of Open Source Infrahub
OpsMill, a pioneer in infrastructure and network automation, today announced the beta release of its open source Infrahub platform. Infrahub unifies previously disparate automation capabilities into a single platform, enabling IT teams to transform all their data center, cloud, network, and security infrastructure operations with scalable and consumable automation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240528726475/en/
Infrahub brings the worlds of infrastructure-as-code and infrastructure management together in a single platform (Graphic: Business Wire)
“I’ve spent years building automation systems for infrastructure and network management across a variety of organizations. At every stop, I encountered the same challenges: Managing network and cloud infrastructure required the use of a confusing, cumbersome, costly mix of solutions. These tools were always hampered by serious technical limitations, such as inflexible data models,” said Damien Garros, CEO and co-Founder, OpsMill. “With the release of Infrahub’s open beta, we’ve drawn on years of experience to solve those challenges. This is the first platform that unites the GitOps Infrastructure-as-Code approach with an extensible structured data model. By combining these two approaches, Infrahub frees infrastructure and automation teams from having to integrate and maintain a fragile set of tools. Instead, they can focus on driving innovation through better automation.”
Infrastructure automation has suffered from an unhelpful divide between GitOps and traditional infrastructure management approaches that prevents teams from gaining the critical advantages and best practices of both approaches. GitOps, an automation approach used by many software development teams, offers version control and continuous integration (CI) validation, which are critical for maintaining an accurate data model while scaling automation use. However, GitOps doesn’t offer a structured data model that most easily represents IT infrastructure components and their many inter-linkages. Traditional infrastructure management approaches offer infrastructure-friendly structured databases, but don’t include version control or CI, and are constrained by fixed data models that limit their flexibility.
Infrahub unifies the best of both worlds in a single platform, including the following key capabilities:
- Extensible Graph Database: Infrahub overcomes the limitations of source-of-truth databases that come with fixed schemas. It is built on an extensible, knowledge-graph database that is ideal for representing and querying the many interrelationships between infrastructure components. Infrahub’s flexible data model means that it can scale across data centers, clouds, networks, and security infrastructure and use cases.
- Version Control: Infrahub makes versioning possible for your entire data model and all the data populated into that model. This means that multiple members of your team can, in parallel, create a branch of the entire infrastructure database, update an infrastructure component in the database in order to generate configuration files for a network change, then merge the updates back into the database. Native versioning of a centralized and extensible infrastructure database is a key innovation of Infrahub.
- Artifact Rendering: Infrahub doesn’t leave you alone in managing the generation of artifacts such as configuration files or reporting data files. It includes native artifact rendering as a native platform capability.
- Continuous Integration (CI): Infrahub has built in the process for performing CI validations to ensure quality control over configuration and data changes.
“As someone who has engineered large backbone networks and helped build a company that relied on extensive network and cloud infrastructure, I’ve seen firsthand how much organizations struggle with scalable and maintainable automation,” said Raphael Maunier, COO and co-Founder, OpsMill. “Infrastructure teams often need their own dev teams just to gather data and build infrastructure, leading to high maintenance costs and slowed innovation. OpsMill was founded to change this. Infrahub provides all the key elements for scalable infrastructure and network automation success, allowing teams to focus on innovation instead of maintaining custom software.”
The open beta version of Infrahub is available now. Visit GitHub to get started today.
About OpsMill
OpsMill is the infrastructure automation platform company, bringing the best practices and features of the industry’s leading automation approaches together in a single, scalable, and extensible platform so that infrastructure, cloud, network, and security teams can focus on innovation rather than integrating toolsets. Infrahub by OpsMill is the industry’s leading open-source integrated infrastructure automation platform. OpsMill is backed by Serena Capital, Partech, OVNI Capital, Kima Ventures and Better Angle. For more information, visit OpsMill.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240528726475/en/
Contact information
Jordan Tewell
10Fold for OpsMill
opsmill@10fold.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 202531.5.2025 15:00:00 EEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Data from the Arm D of SEQUOIA demonstrate that treatment with BRUKINSA plus venetoclax has the potential to drive progression-free survival and overall deep and durable responses across the frontline CLL patient spectrum, including patients with high-risk mutational status. The best undetectable minimal residual disease (uMRD) rate in peripheral blood at a sensitivity level 10-4 was 59%. These efficacy responses observed in Arm D, despite the high proportion of high-risk patients enrolled, are in
You Up? Grindr’s “Right Now” Goes Global30.5.2025 16:00:00 EEST | Press release
Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded people without wasting time on mismatched expectations. The response to our initial March launc
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 15:00:00 EEST | Press release
Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative financing approaches to manage the costs of treatment and care. “Despite CAR T-cell therapy being available in the United States for nearly seven years in large B-cell lymphoma, only approximately two out of 10 eligible patients with some advanced blood cancers ever receive CAR T-cell therapy,” said Miguel Perale
Indian Educationist Dr. Achyuta Samanta Recognised With Research Institute in His Name at CUNY, USA30.5.2025 12:17:00 EEST | Press release
In a noteworthy development underscoring growing academic collaboration between India and the United States, the City University of New York (CUNY) has launched a dedicated research platform—the Achyuta Samanta India Initiative of the CUNY CREST Institute (ASIICCI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529012005/en/ Dr. Milton Santiago, President of Bronx Community College, and Dr. Achyuta Samanta, Founder of KIIT & KISS, jointly inaugurate the Achyuta Samanta India Initiative of CUNY CREST Institute (ASIICCI) with a ribbon-cutting ceremony in New York. Named after Dr. Achyuta Samanta, a noted Indian educationist and social worker, the initiative focuses on academic research in Indian social and educational sectors, with a particular lens on Odisha. This marks one of the rare instances of a living Indian being honoured with such a naming in an American public university system. Dr. Samanta, who hails from Odisha
FDA Grants De Novo Clearance for Reflow Medical's Spur ® Peripheral Retrievable Stent System30.5.2025 07:08:00 EEST | Press release
Reflow Medical, Inc., a leading developer of innovative medical devices focused on complex cardiovascular disease, announced that the U.S. Food and Drug Administration (FDA) has granted De Novo clearance for the company’s Spur Peripheral Retrievable Stent System, a unique clinical solution for the treatment of de novo or restenotic lesions following predilatation in patients with infrapopliteal arterial disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529610368/en/ The first and only retrievable stent system that features a self-expanding stent with an integrated dilatation balloon catheter on an over-the-wire system. It is designed for controlled lesion penetration and treatment through a series of radially expandable spikes. Known as Retrievable Scaffold Therapy (RST), the spikes on the Spur Stent penetrate the lesion to increase the acute luminal diameter and modify the lesion morphology to change vessel complia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom